Bioabsorable Stent May Reduce MACE Related to DES
February 19, 2008 – A novel, fully bioabsorbable salicylate-based stent offers the potential to reduce adverse events associated with current drug-eluting stents (DES) and could be very beneficial to patients with coronary heart disease, according to a presentation at the Cardiovascular Revascularization Therapies 2008 (CRT) symposium.
Refat Jabara, M.D., of the scientific team from Atlanta-based Saint Joseph’s Translational Research Institute (SJTRI), presented his abstract "Novel Anti-Inflammatory Salicylate-Based Bioabsorbable Drug-Eluting Polymeric Coating" from the podium during oral presentations of the 'Best Ten Abstracts' category. Dr. Jabara received Top Five Abstract Award honors for the work from the course chairman, Ron Waksman, M.D.
“At SJTRI, we are in the process of evaluating several variations of the next generation of intravascular stents. As demonstrated in this study, the technology of a fully bioabsorbable stent platform could lead to dramatic advances in the clinical treatment of patients with coronary heart disease. I am fortunate to be able to contribute to the assessment of these devices and the impact that they may have on the health and welfare of patients around the world,” said Dr. Jabara.
For more information: www.crtonline.org